Envista (NYSE:NVST) Price Target Increased to $23.00 by Analysts at Evercore ISI

Envista (NYSE:NVST) had its price objective increased by Evercore ISI from $18.00 to $23.00 in a research note issued to investors on Monday morning, Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other research analysts also recently issued reports on NVST. JPMorgan Chase & Co. downgraded shares of Envista from an overweight rating to a neutral rating and reduced their price target for the stock from $23.00 to $16.00 in a research report on Thursday, August 8th. Stifel Nicolaus decreased their target price on Envista from $20.00 to $18.00 and set a buy rating for the company in a research note on Tuesday, July 30th. Robert W. Baird lowered their target price on Envista from $19.00 to $17.00 and set a neutral rating for the company in a report on Monday, July 22nd. Needham & Company LLC reissued a hold rating on shares of Envista in a report on Thursday, August 8th. Finally, Piper Sandler lowered their price objective on Envista from $18.00 to $16.00 and set a neutral rating for the company in a research note on Tuesday, July 30th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of Hold and an average price target of $19.59.

Envista Stock Up 3.2 %

Shares of Envista stock opened at $19.24 on Monday. The business has a 50-day moving average price of $17.55 and a 200 day moving average price of $18.44. Envista has a fifty-two week low of $15.15 and a fifty-two week high of $28.67. The firm has a market cap of $3.31 billion, a P/E ratio of -26.72 and a beta of 1.31. The company has a quick ratio of 1.90, a current ratio of 2.22 and a debt-to-equity ratio of 0.47.

Envista (NYSE:NVST) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.27 by ($0.16). Envista had a negative net margin of 52.25% and a positive return on equity of 4.86%. The firm had revenue of $633.10 million during the quarter, compared to the consensus estimate of $646.88 million. During the same quarter last year, the firm posted $0.43 earnings per share. Envista’s revenue was down 4.4% compared to the same quarter last year. On average, sell-side analysts forecast that Envista will post 0.69 earnings per share for the current fiscal year.

Insider Buying and Selling at Envista

In related news, CFO Eric D. Hammes purchased 24,532 shares of Envista stock in a transaction dated Monday, August 12th. The stock was bought at an average cost of $16.33 per share, with a total value of $400,607.56. Following the purchase, the chief financial officer now owns 24,532 shares in the company, valued at approximately $400,607.56. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 1.30% of the stock is owned by corporate insiders.

Institutional Trading of Envista

Several institutional investors have recently modified their holdings of the company. Versant Capital Management Inc raised its position in Envista by 1,420.3% in the second quarter. Versant Capital Management Inc now owns 3,147 shares of the company’s stock worth $52,000 after acquiring an additional 2,940 shares in the last quarter. Innealta Capital LLC acquired a new position in shares of Envista in the 2nd quarter worth approximately $78,000. Summit Securities Group LLC acquired a new position in shares of Envista in the 2nd quarter worth approximately $85,000. Signaturefd LLC lifted its stake in Envista by 85.9% during the second quarter. Signaturefd LLC now owns 5,345 shares of the company’s stock valued at $89,000 after purchasing an additional 2,470 shares during the last quarter. Finally, Johnson Financial Group Inc. acquired a new stake in Envista during the fourth quarter valued at approximately $136,000.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.